GeneNews in pact for first personalized medicine center in China

GeneNews (TSX:GEN) has signed a memorandum of understanding with Shanghai Biochip, a leading Chinese engineering center for advanced microarray and gene expression profiling technologies, for a strategic alliance to establish the first Sentinel Centre for Personalized Medicine in China. GeneNews and SBC would jointly establish and manage the Sentinel Centre for Personalized Medicine to co-develop [...]

GeneNews platform identifies blood biomarkers for NPC

In a presentation at the 2011 Asia Pacific Cancer Conference, GeneNews (TSX:GEN) reported that a study using its proprietary Sentinel Principle platform technology identified blood-based biomarkers that distinguished nasopharyngeal carcinoma (NPC) patients from controls and from patients with other cancers with high accuracy. NPC is a common cancer in certain parts of Northern Africa and [...]

GeneNews launches ColonSentry in Malaysia

GeneNews (TSX:GEN) has announced the commercial launch of ColonSentry, the world’s first blood-based test to determine a person’s current risk for colorectal cancer, in Malaysia through its GeneNews Diagnostics Sdn. Bhd. subsidiary. “We are excited that GeneNews Diagnostics will now be able to provide the Malaysian population with access to this potentially life-saving colorectal cancer [...]

GeneNews holders okay stock consolidation

Shareholders of GeneNews (TSX:GEN) at a special meeting approved a proposed share consolidation of the basis of one post-consolidation common share for every six pre-consolidation common shares. The timing for implementation of the consolidation will be determined by the company’s board of directors, but will be no later than Jan. 31, 2012. “We believe that [...]

GeneNews launches SentinelGx

GeneNews (TSX: GEN) has launched SentinelGx, a suite of pharmacogenomic and companion diagnostic BloodRNA services for drug development and personalized health management applications. SentinelGx services provide complete whole blood transcriptome analysis for RNA expression profiling of inflammatory pathways, immune system response and cell signalling based on the company’s patented Sentinel Principle technology. A catalog of [...]

Schizophrenia biomarkers found by GeneNews’ Sentinel Principle

A study using GeneNews’ (TSX:GEN) Sentinel Principle platform technology to identify complex changes in blood gene expression patterns that may be indicative of underlying risk factors for schizophrenia will be published in the American Journal of Medical Genetics Part B and is currently available online. “This study shows that we can identify a gene signature [...]

GeneNews technology able to predict risk of liver cancer for patients with chronic hepatitis

A poster entitled “Biomarkers to predict risk of subsequent hepatocellular cancer in patients with chronic hepatitis,” describing the initial phase of analysis of a 1,600-cohort study using GeneNews’ (TSX:GEN) Sentinel Principle, was presented at the 9th Liver Update 2011 conference in Malaysia. The poster reports on the application of the Sentinel Principle platform technology to [...]

GeneNews closes warrant exercise incentive program

GeneNews (TSX:GEN) has completed an early warrant exercise incentive program and debenture conversion, raising almost $3 million. A total of 74% of eligible warrants were exercised and the company issued 12.8 million common shares and 12.8 million incentive warrants. In addition, holders of 25% of eligible convertible debentures participated in the debenture conversion, resulting in [...]

GeneNews holders okay early warrant campaign

Shareholders of GeneNews (TSX:GEN) at the annual meeting approved an early warrant exercise incentive program to run from May 17 to June 8. If all warrants eligible to participate in the program are exercised during the 22-day period, the company expects it will receive gross proceeds of up to about $4.1-million, and issue up to [...]

Personalized medicine is more than targeted therapeutics

That’s a message Enzo Biochem (NYSE:ENZ) wants to get out. “We are positioned extremely well for personalized medicine in the sense that as new immunoassays are recommended by the various professional societies, we are able to move them into the market very quickly because of our broad range of technology and licensure,” David Goldberg, VP [...]

Next Page »